Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avantis US Small Cap Value ETF (AVUV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Avantis US Small Cap Value ETFTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Avantis US Small Cap Value ETF vs Recursion Pharmaceuticals Inc — how do they compare? Avantis US Small Cap Value ETF trades at $127.31, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AVUVRXRX
Sector
Sector/ThematicHealth
52-Week High
$128.74$6.79
52-Week Low
$93.93$2.84
Market Cap
$1.78B
Enterprise Value
$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avantis US Small Cap Value ETF

AVUV trades at $126.88, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights strong small-cap value performance and potential benefits from rate outlook shifts. The ETF focuses on U.S. small-cap value stocks, offering diversification from tech-heavy portfolios.

Outlook remains positive due to small-cap momentum and value factor tailwinds, but risks include higher volatility and sensitivity to interest rates. Analyst sentiment is favorable, emphasizing long-term growth potential in tax-advantaged accounts like Roth IRAs.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Avantis US Small Cap Value ETF

AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.

Read more on AVUV

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX